Home › Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
 

Keywords :   


Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event

2015-11-03 04:51:04| drugdiscoveryonline Home Page

Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, recently announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study), phase 1 preliminary results from the ACE-083 program, and its new IntelliTrapdrug discovery platform

Tags: day results research development

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
25.04AkzoNobel Shareholders Approve all Resolutions at Annual General Meeting
25.04US economic growth slows but inflation grows
25.04Hamillroad Software to preview Next Generation Bellissima DMS
25.04SNF Introduces Natursol EMI Lite
25.04Sephora Launches Drunk Elephant Across Omnichannel Touchpoints in Mainland China
25.04FDA Reopens Comment Period on Increased Color Additive Certification Fees
25.04BASF Reports Solid Start to the Year in 1Q 2024
25.04Google accused of making it harder to search for rival
More »